ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,068.50
      0.03%
      US Tech 100
      21,138.80
      -0.15%
      Dow Jones
      44,593.65
      0.28%
      Brent Oil
      76.56
      -0.10%
      Bitcoin
      95,833.59
      0.09%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lyell Immunopharma Inc (LYEL)

      7. Lyell Immunopharma Inc (LYEL) News

      Lyell Immunopharma Inc

      Lyell Immunopharma Inc (LYEL)

      NASDAQ
      0.5448
      -0.0087
      (-1.57%)
      Closed February 12 4:00PM
      Delayed by 15 minutes
      0.5448
      -0.0052
      (-0.95%)
      After Hours: 7:22PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      LYEL News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 24 2025
      LYEL (-1.57%)

      Form 8-K/A - Current report: [Amend]
      Edgar (US Regulatory)
      January 10 2025
      LYEL (-1.57%)

      Form 424B5 - Prospectus [Rule 424(b)(5)]
      Edgar (US Regulatory)
      December 09 2024
      LYEL (-1.57%)

      Form EFFECT - Notice of Effectiveness
      Edgar (US Regulatory)
      December 06 2024
      LYEL (-1.57%)

      Form S-3 - Registration statement under Securities Act of 1933
      Edgar (US Regulatory)
      November 29 2024
      LYEL (-1.57%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 26 2024
      LYEL (-1.57%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 07 2024
      LYEL (-1.57%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      October 31 2024
      LYEL (-1.57%)

      LYEL Discussion

      View Posts
      jondoeuk jondoeuk 1 week ago
      There are other bi-specific CARs, including two by GILD's Kite, and at least one tri-specific in development as well.

      CRGX's CRG-023 (IND cleared, PhI mid-year) is the first tri-specific CAR-T to express three independent CARs from a single vector, with each CAR having a distinct co-stim domain. One co-stim domain incorporates CD2 signaling, which has been designed to overcome immune-evasion mediated by the loss of CD58 https://ashpublications.org/blood/article/136/Supplement%201/53/470303/CD58-Aberrations-Limit-Durable-Responses-to-CD19

      Novel CD19 and CD20 scFvs were selected for enhanced CAR performance and combined with the existing CD22 scFv used in firi-cel. These new binders are fully human to limit host-mediated rejection. The iterative engineering allowed for the selection of the optimal costimulatory domain configuration and optimal assemblage in the lentiviral vector used https://www.sciencedirect.com/science/article/pii/S0006497124047827
      👍️0
      jondoeuk jondoeuk 1 week ago
      What they don't say is equally as important as what they do say.

      Prizlon-cel, is a novel CD19/CD20 bispecific CAR-T. Of the 48 patients infused, 44 had LBCL. No patient experienced a DLT. CRS occurred in 93.8% of patients, with only one case of grade 3. ICANS occurred in 6.3% of patients, with no grade 3 or higher events. The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow up of 30.0 months, median DOR, PFS, and OS were all not reached. The Kaplan-Meier estimate of 2-year DOR, PFS and OS rates were 66.0%, 62.6%, and 76.5%, respectively. https://ashpublications.org/blood/article/doi/10.1182/blood.2024026401/535112/A-phase-1-trial-of-prizloncabtagene-autoleucel-a

      The company behind it has signed deals with both AstraZeneca and Janssen. The latter includes this CAR (and another targeting just CD20), which has been granted Regenerative Medicine Advanced Therapy and Fast Track designations by the FDA for the treatment of patients with R/R DLBCL. Now a PhI/II trial is ongoing https://clinicaltrials.gov/study/NCT05800977
      👍️0
      jondoeuk jondoeuk 1 week ago
      An update https://www.biospace.com/press-releases/lyell-to-highlight-vision-for-its-next-generation-car-t-cell-therapy-pipeline-at-43rd-annual-jp-morgan-healthcare-conference

      See slide 10 https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
      👍️0
      glenn1919 glenn1919 1 month ago
      LYEL.................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 3 months ago
      lyel..............................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 3 months ago
      LYEL................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 4 months ago
      As a reminder, the ORR was ~12.5% for LYL797. BMY's JCAR024 had an ORR of 5-6%, but was discontinued, while a Fred Hutch construct showed no responses.
      👍️0
      jondoeuk jondoeuk 4 months ago
      An update https://www.globenewswire.com/news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html

      The webcast https://lyell-company-update-2024.open-exchange.net/registration

      Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0
      👍️0
      glenn1919 glenn1919 4 months ago
      LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 5 months ago
      Preclinical data (Stim-R tech) https://www.nature.com/articles/s41598-024-72392-1
      👍️0
      glenn1919 glenn1919 6 months ago
      LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 8 months ago
      (OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

      They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

      Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418
      🎯 1 👍️ 1
      glenn1919 glenn1919 10 months ago
      LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 10 months ago
      LYEL active in the Gaucho session

      👍️0
      jondoeuk jondoeuk 10 months ago
      Tempting but I will remain on the sidelines.
      👍️0
      Monksdream Monksdream 10 months ago
      LYEL under $3
      👍️0
      glenn1919 glenn1919 11 months ago
      LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 1 year ago
      They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html
      👍️0
      jondoeuk jondoeuk 1 year ago
      Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
      👍️0
      Monksdream Monksdream 1 year ago
      LYEL new 52 week low
      👍️0
      jondoeuk jondoeuk 2 years ago
      LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739
      👍️0
      jondoeuk jondoeuk 2 years ago
      Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full
      👍️0
      glenn1919 glenn1919 2 years ago
      LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
      👍️0
      jondoeuk jondoeuk 2 years ago
      The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
      👍️0
      jondoeuk jondoeuk 2 years ago
      SITC titles

      NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

      Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

      The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

      The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

      Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
      👍️0
      NY1972 NY1972 3 years ago
      recent technical advances using culture conditions with IL-7/IL-15 and
      the addition of IL-21 may enhance the enrichment for TSCM cells
      in the final CART product (74–76), which can be further increased
      with the addition of drugs blocking T-cell differentiation, such as
      glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
      have not been developed so far. Recently, a few CART19 clinical
      trials for DLBCL have been conducted in which CART products
      were manufactured from CD62L+ isolated T cells to generate
      cellular products enriched for TCM cells (21, 78); however, due to
      prolonged culture conditions, enrichment for TSCM and TCM
      subsets in the infused product could not be demonstrated

      https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full
      👍️0
      jondoeuk jondoeuk 3 years ago
      The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

      * Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
      👍️0
      NY1972 NY1972 3 years ago
      Thanks for the link.
      Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

      Compared to T-Charge
      http://www.koreabiomed.com/news/articleView.html?idxno=12767

      👍️0
      jondoeuk jondoeuk 3 years ago
      For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522
      👍️0
      NY1972 NY1972 3 years ago
      Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
      or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
      YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia
      👍️0
      jondoeuk jondoeuk 3 years ago
      That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.
      👍️0
      NY1972 NY1972 3 years ago
      Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?
      👍️0
      jondoeuk jondoeuk 3 years ago
      ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373
      👍️0
      jondoeuk jondoeuk 3 years ago
      Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

      https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4
      👍️0
      jondoeuk jondoeuk 3 years ago
      1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

      661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
      👍️0
      jondoeuk jondoeuk 3 years ago
      GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

      This uses Epi-R.
      👍️0
      jondoeuk jondoeuk 3 years ago
      AACR poster https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6
      👍️0
      jondoeuk jondoeuk 3 years ago
      The PhI (n=54) of LYL797 has now been listed. The dose-escalation phase (TNBC only) will investigate four dose levels to determine the recommended RP2D. The dose expansion will enroll both TNBC and NSCLC.
      👍️0
      jondoeuk jondoeuk 3 years ago
      A new review https://www.sciencedirect.com/science/article/pii/S0952791521001278
      👍️0
      jondoeuk jondoeuk 3 years ago
      Morgan Stanley webcast https://morganstanley.webcasts.com/viewer/event.jsp?ei=1488969&tp_key=3cedc4a917
      👍️0
      jondoeuk jondoeuk 4 years ago
      New deck https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
      👍️0

      Your Recent History

      NASDAQ
      LYEL
      Lyell Immunopharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads